The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure

被引:79
作者
Zhao, JH
Wang, MJ
Chen, J
Luo, AP
Wang, XQ
Wu, M
Yin, DL
Liu, ZH
机构
[1] Peking Union Med Coll, Inst Canc, Natl Lab Mol Oncol, Beijing 100021, Peoples R China
[2] Chinese Acad Med Sci, Beijing 100021, Peoples R China
[3] Peking Union Med Coll, Inst Mat Med, Beijing 100050, Peoples R China
[4] Chinese Acad Med Sci, Beijing 100050, Peoples R China
基金
中国国家自然科学基金;
关键词
p53; HDM2; nonpeptidic small molecule HDM2 inhibitor;
D O I
10.1016/S0304-3835(02)00084-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Peptidic Mouse Double Minute (MDM2) inhibitors have been demonstrated to effectively inhibit the interaction between p53 and MDM2, thus providing a therapeutic strategy for some tumors. However, there is no report on non-peptidic inhibitors. In this study non-peptidic HDM2 (the human homologue of MDM2) inhibitors were obtained by computer-aided design and subsequently synthesized by chemical method. Bio-evaluation showed that some of these inhibitors have affinity with HDM2, and can cause death of some turner cells which express wild-type p53. Cellular assays showed that one of these compounds, syc-7, can activate the p53 pathway in some of these tumor cell lines, and further induce apoptosis. The results suggest that developing non-peptidic small-molecule HDM2 inhibitors is a promising way for new antitumor drug discovery. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:69 / 77
页数:9
相关论文
共 18 条
[1]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[2]   Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2 [J].
Blaydes, JP ;
Gire, V ;
Rowson, JM ;
WynfordThomas, D .
ONCOGENE, 1997, 14 (15) :1859-1868
[3]   Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].
Bottger, A ;
Bottger, V ;
Sparks, A ;
Liu, WL ;
Howard, SF ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (11) :860-869
[4]  
Bottger V, 1996, ONCOGENE, V13, P2141
[5]   A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines [J].
Chène, P ;
Fuchs, J ;
Bohn, J ;
García-Echeverría, C ;
Furet, P ;
Fabbro, D .
JOURNAL OF MOLECULAR BIOLOGY, 2000, 299 (01) :245-253
[6]   Mdm2 promotes the rapid degradation of p53 [J].
Haupt, Y ;
Maya, R ;
Kazaz, A ;
Oren, M .
NATURE, 1997, 387 (6630) :296-299
[7]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[8]   Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain [J].
Kussie, PH ;
Gorina, S ;
Marechal, V ;
Elenbaas, B ;
Moreau, J ;
Levine, AJ ;
Pavletich, NP .
SCIENCE, 1996, 274 (5289) :948-953
[9]   MDM2 - arbiter of p53's destruction [J].
Lane, DP ;
Hall, PA .
TRENDS IN BIOCHEMICAL SCIENCES, 1997, 22 (10) :372-374
[10]   P53 AND HUMAN CANCERS [J].
LANE, DP .
BRITISH MEDICAL BULLETIN, 1994, 50 (03) :582-599